Drug Profile
Telazorlimab - Ichnos Sciences
Alternative Names: GBR-830; ISB-830Latest Information Update: 18 Apr 2024
Price :
$50
*
At a glance
- Originator Glenmark Pharmaceuticals S.A.
- Developer Glenmark Pharmaceuticals S.A.; Ichnos Sciences
- Class Anti-inflammatories; Antirheumatics; Monoclonal antibodies; Skin disorder therapies
- Mechanism of Action OX40 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II Atopic dermatitis
- Preclinical Rheumatoid arthritis
- No development reported Systemic lupus erythematosus; Ulcerative colitis
Most Recent Events
- 04 Mar 2024 Astria Therapeutics in-licenses four pending U.S. patent applications and three pending European patent applications directed to telazorlimab uses and formulations
- 04 Mar 2024 Astria Therapeutics in-licenses six patent families from Ichnos directed to telazorlimab and telazorlimab-containing formulations, and their use
- 30 Jan 2024 Glenmark and Ichnos enters into an alliance to form 'Ichnos Glenmark Innovation'